EUVIMEDEUVIMED entdecken
Crossref

Development of STING degrader with double covalent ligands

Miki Nakamura, Nobumichi Ohoka, Norihito Shibata, Takao Inoue, Genichiro Tsuji, Yosuke Demizu

Bioorganic & Medicinal Chemistry Letters · 2024-04 · 102 · 129677

DOI: 10.1016/j.bmcl.2024.129677 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2024-04. Verfasst von Miki Nakamura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Division of Pharmaceutical Science of Okayama University, 1-1-1, Tsushimanaka, Ki…. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, Signal Transduction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stimulator of interferon genes (STING), a homodimeric membrane receptor localized in the endoplasmic reticulum, plays a pivotal role in signaling innate immune responses. Inhibitors and proteolysis-targeting chimeras (PROTACs) targeting STING are promising compounds for addressing autoinflammatory and autoimmune disorders. In this study, we used a minimal covalent handle recently developed as the ligand portion of an E3 ligase. The engineered STING degrader with a low molecular weight compound covalently binds to STING and E3 ligase. Degrader 2 showed sustained STING degradation activity at lower concentrations (3 µM, 48 h, about 75 % degradation) compared to a reported STING PROTAC, SP23. This discovery holds significance for its potential in treating autoinflammatory and autoimmune diseases, offering promising avenues for developing more efficacious STING-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Protein LigasesSignal TransductionProteolysisLigands

Stichwörter der Autor:innen

Covalent ligandDrug designProtein degradationSTING

Substanzen

LigandsUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Division of Pharmaceutical Science of Okayama University, 1-1-1, Tsushimanaka, Kita 700-8530, Japan; Division of Organic Chemistry, National Institute…
  • Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa 210-9501, Japan. Electronic address: n-ohoka@nihs.go.jp.
  • Division of Biochemistry, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa 210-9501, Japan.
  • Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa 210-9501, Japan.
  • Division of Organic Chemistry, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa 210-9501, Japan. Electronic address: gtsuji@nihs.go.jp.

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Nakamura, M., Ohoka, N., Shibata, N., Inoue, T., Tsuji, G., & Demizu, Y. (2024). Development of STING degrader with double covalent ligands. Bioorganic & Medicinal Chemistry Letters, 102, 129677. https://doi.org/10.1016/j.bmcl.2024.129677

Vancouver

Nakamura M, Ohoka N, Shibata N, Inoue T, Tsuji G, Demizu Y. Development of STING degrader with double covalent ligands. Bioorganic & Medicinal Chemistry Letters. 2024;102:129677. doi:10.1016/j.bmcl.2024.129677

BibTeX
@article{Nakamura2024,
  author = {Nakamura, Miki and Ohoka, Nobumichi and Shibata, Norihito and Inoue, Takao and Tsuji, Genichiro and Demizu, Yosuke},
  title = {Development of STING degrader with double covalent ligands},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2024},
  volume = {102},
  pages = {129677},
  doi = {10.1016/j.bmcl.2024.129677}
}
Kostenlos starten →